Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells

Tang, Feng; Cho, Hsin Ju; Pai, Man Hui; Chen, Ye Hsin

doi:10.1016/j.jnutbio.2008.05.001

Cited by 75 publications

(41 citation statements)

References 34 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, lycopene and fish oil inhibited tumor progression and inflammation through suppression of MMP-7, MMP-9, COX-2, and PGE2. Similar synergistic inhibitory effects on the proliferation of colon cancer cells by lycopene and eicosapentaenoic acid (EPA), a major component in fish oil, even at low concentration were reported by Tang et al [74]. The inhibitory mechanism was associated with suppression of PI3K/Akt/mTOR signaling pathway and upregulation of apoptotic proteins such as Bax and Fas ligand.…”

Section: Potential Mechanisms Of Actions Of Lycopenesupporting

confidence: 62%

“…Tang et al [74] reported that lycopene and EPA (eicosapentaenoic acid) synergistically inhibit the activation of AKT and mammalian target of rapamycin (mTOR), enhancing the accumulation of Bax and Fas ligand and blocking the survival of HT-29 human colon cancer cells. Moreover, in combination with S-allyl cysteine, lycopene significantly blocks the in vivo development of gastric cancer by inducing apoptosis via reduced expression of Bcl-2, increased expression of Bax and Bim, and increased activation of caspases 8 and 3 [75].…”

Section: Potential Mechanisms Of Actions Of Lycopenementioning

confidence: 99%

See 1 more Smart Citation

Multiple Molecular and Cellular Mechanisms of Action of Lycopene in Cancer Inhibition

Trejo-Solís

Pedraza‐Chaverrí

Torres-Ramos

et al. 2013

Evidence-Based Complementary and Alternative Medicine

118

View full text Add to dashboard Cite

Epidemiological studies suggest that including fruits, vegetables, and whole grains in regular dietary intake might prevent and reverse cellular carcinogenesis, reducing the incidence of primary tumours. Bioactive components present in food can simultaneously modulate more than one carcinogenic process, including cancer metabolism, hormonal balance, transcriptional activity, cell-cycle control, apoptosis, inflammation, angiogenesis and metastasis. Some studies have shown an inverse correlation between a diet rich in fruits, vegetables, and carotenoids and a low incidence of different types of cancer. Lycopene, the predominant carotenoid found in tomatoes, exhibits a high antioxidant capacity and has been shown to prevent cancer, as evidenced by clinical trials and studies in cell culture and animal models. In vitro studies have shown that lycopene treatment can selectively arrest cell growth and induce apoptosis in cancer cells without affecting normal cells. In vivo studies have revealed that lycopene treatment inhibits tumour growth in the liver, lung, prostate, breast, and colon. Clinical studies have shown that lycopene protects against prostate cancer. One of the main challenges in cancer prevention is the integration of new molecular findings into clinical practice. Thus, the identification of molecular biomarkers associated with lycopene levels is essential for improving our understanding of the mechanisms underlying its antineoplastic activity.

show abstract

Section: Potential Mechanisms Of Actions Of Lycopenesupporting

confidence: 62%

Section: Potential Mechanisms Of Actions Of Lycopenementioning

confidence: 99%

Multiple Molecular and Cellular Mechanisms of Action of Lycopene in Cancer Inhibition

Trejo-Solís

Pedraza‐Chaverrí

Torres-Ramos

et al. 2013

Evidence-Based Complementary and Alternative Medicine

118

View full text Add to dashboard Cite

show abstract

“…In human colon cancer cells and primary cultures of rat colonic crypts, enhanced induction of apoptosis observed with the combination of butyrate and DHA appeared to occur through a p53-independent mechanism that relied on the upregulation of the mitochondrial Ca 2+ -dependent pathway (Kolar et al 2007). Lycopene and EPA in combination demonstrated a significant reduction of cell proliferation in HT29 colon cancer cells (p < 0.05), which was associated with inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway (Tang et al 2009). …”

Section: Introductionmentioning

confidence: 97%

Diet-Based Strategies for Cancer Chemoprevention: The Role of Combination Regimens Using Dietary Bioactive Components

DiMarco-Crook

Xiao

2015

Annu. Rev. Food Sci. Technol.

View full text Add to dashboard Cite

Chemopreventive agents that the general population can consume for prolonged periods of time with minimal risk of any side effects are of great interest to all in search of a solution to the pervasive incidence of cancer. Dietary bioactive components have been found to modulate many deregulated molecular pathways associated with the initiation and progression of different types of cancer. Combination regimens with dietary bioactive components are a promising strategy for cancer chemoprevention because they may offer enhanced protective effects against cancer development but cause little or no adverse effects. This article provides an overview of studies examining the combination of dietary bioactive components for the chemoprevention of major types of cancer. A better understanding of existing research on the combination of dietary bioactive components will provide an important basis for the rational design of future combination studies and the successful development of cancer chemoprevention strategies.

show abstract

“…These compounds, including curcumin from a spice turmeric [74] , epigallocatechin-3-gallate from green tea [87] and lycopene from tomato [88] , could target important mechanisms in tumour growth and metastasis [89] . Screening drugs from traditional Chinese medicine has been suggested as a shortcut in searching for new leading compounds.…”

Section: Hlj1 As a Molecular Target In Anticancer Therapiesmentioning

confidence: 99%

Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer

Tsai¹

2014

WJCO

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality throughout the world. Non-small cell lung cancer (NSCLC) accounts for 85% of all diagnosed lung cancers. Despite considerable progress in the diagnosis and treatment of the disease, the overall 5-year survival rate of NSCLC patients remains lower than 15%. The most common causes of death in lung cancer patients are treatment failure and metastasis. Therefore, developing novel strategies that target both tumour growth and metastasis is an important and urgent mission for the next generation of anticancer therapy research. Heat shock proteins (HSPs), which are involved in the fundamental defence mechanism for maintaining cellular viability, are markedly activated during environmental or pathogenic stress. HSPs facilitate rapid cell division, metastasis, and the evasion of apoptosis in cancer development. These proteins are essential players in the development of cancer and are prime therapeutic targets. In this review, we focus on the current understanding of the molecular mechanisms responsible for HLJ1's role in lung cancer carcinogenesis and progression. HLJ1, a member of the human HSP 40 family, has been characterised as a tumour suppressor. Research studies have also reported that HLJ1 shows promising dual anticancer effects, inhibiting both tumour growth and metastasis in NSCLC. The accumulated evidence suggests that HLJ1 is a potential biomarker and treatment target for NSCLC.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Non-small cell lung cancer; Metastasis; HLJ1; Anticancer; Biomarker Core tip: HLJ1, a member of the human heat shock proteins 40 family, has been characterised as a tumour suppressor. Research studies have reported that HLJ1 shows promising dual anticancer effects, inhibiting both tumour growth and metastasis in non-small cell lung cancer (NSCLC). The accumulated evidence suggests that HLJ1 is a potential biomarker and treatment target for NSCLC. We propose a hypothetical model for the roles of HLJ1 stimulator in suppressing lung cancer tumourigenesis. Investigating the integrated and coordinated molecular mechanisms of HLJ1 may shed new light on the treatment of lung cancer. The development of drug targeting HLJ1 may be an effective approach for lung cancer therapy.Tsai MF, Wang CC, Chen JJW. Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in nonsmall cell lung cancer.

show abstract

Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells

Cited by 75 publications

References 34 publications

Multiple Molecular and Cellular Mechanisms of Action of Lycopene in Cancer Inhibition

Multiple Molecular and Cellular Mechanisms of Action of Lycopene in Cancer Inhibition

Diet-Based Strategies for Cancer Chemoprevention: The Role of Combination Regimens Using Dietary Bioactive Components

Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer

Contact Info

Product

Resources

About